Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.
- Salmen A Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
- von Ahsen N Medizinisches Labor Bremen, Germany.
- Trampe AK Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
- Hoepner R Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
- Plavina T Biogen, Cambridge, MA, USA.
- Subramanyam M Biogen, Cambridge, MA, USA.
- Kuesters G Biogen, Cambridge, MA, USA.
- Gold R Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
- Chan A Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany; Current address: Ambulantes Neurozentrum, Inselspital, Bern University Hospital, Bern, Switzerland.
- 2017-06-14
Published in:
- Multiple sclerosis journal - experimental, translational and clinical. - 2016
English
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2-2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8-17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1-3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0-3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3-90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1177/2055217316630008
- PMID 28607714
- Persistent URL
- https://sonar.ch/global/documents/193033
Statistics
Document views: 16
File downloads:
- Full-text: 0